RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors
10 November 2021 - 8:01AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in inflammatory
diseases and oncology, today announced the appointment of Lori
Lyons-Williams, a 20-year industry veteran, to its Board of
Directors.
“We are very excited to welcome Lori to RAPT’s
board of directors,” said Brian Wong, M.D., Ph.D., President and
CEO of RAPT Therapeutics. “Her strong track record of driving
strategic and commercial success across both biotech and
pharmaceutical products will be invaluable as we continue to
advance our pipeline of promising inflammation and oncology product
candidates.”
Ms. Lyons-Williams is President and Chief
Operating Officer at Neumora Therapeutics, a clinical-stage
biotechnology company pioneering precision medicines for brain
diseases. In her current role, Ms. Lyons-Williams is responsible
for research and development, external affairs, CMC/manufacturing,
program management and new product planning. Prior to Neumora, she
served as Chief Commercial Officer of Dermira, a publicly traded
biotech focused on medical dermatology including atopic dermatitis,
until its acquisition. Previously, as Vice President of Sales and
Marketing at Allergan, Lori built an emerging neurotoxin franchise,
successfully launched multiple products and expanded the pipeline
through external collaborations and strategic transactions. Lori
currently serves as an independent director on the board of
Pipeline Therapeutics, a biopharmaceutical company focused on the
development and commercialization of first-in-class small molecules
for neuroregeneration. She was previously an independent director
on the board of Five Prime Therapeutics, a clinical-stage biotech
focused on the discovery and development of protein therapeutics in
immuno-oncology, until its acquisition. Ms. Lyons-Williams holds an
MBA from the Carlson School of Management at the University of
Minnesota and a BA from Virginia Tech. She is a member of Executive
Women in Bio’s Boardroom Ready, an executive leadership program
working to diversify life science corporate boards by championing
women from the C-suite to the boardroom.
“I see the potential of RAPT’s pipeline to
meaningfully improve the lives of people living with inflammatory
disease and cancer, and I am particularly encouraged by the broad
opportunity for RPT193 in atopic dermatitis and allergic diseases
given my prior experience in these therapeutic areas. As
RPT193 and FLX475 continue to progress, I look forward to
collaborating with the RAPT management team and board members as we
work to advance the company and these novel candidates which have
shown initial clinical promise.”
About RAPT Therapeutics,
Inc.RAPT Therapeutics is a clinical stage immunology-based
biopharmaceutical company focused on discovering, developing and
commercializing oral small molecule therapies for patients with
significant unmet needs in inflammatory diseases and oncology.
Utilizing its proprietary discovery and development engine, the
Company is developing highly selective small molecules designed to
modulate the critical immune drivers underlying these diseases.
RAPT has discovered and advanced two unique drug candidates, RPT193
and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4),
for the treatment of inflammation and cancer, respectively. The
Company is also pursuing a range of targets that are in the
discovery stage of development.
Forward-Looking StatementsThis
press release contains forward-looking statements. These statements
relate to future events and involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future performances or achievements expressed or implied by the
forward-looking statements. Each of these statements is based only
on current information, assumptions and expectations that are
inherently subject to change and involve a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements about the progress of RAPT’s oncology and
inflammation programs. Detailed information regarding risk factors
that may cause actual results to differ materially from the results
expressed or implied by statements in this press release may be
found in RAPT’s Form 10-Q filed with the Securities and Exchange
Commission on August 11, 2021 and subsequent filings made by RAPT
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. RAPT disclaims any
obligation to update these forward-looking statements.
RAPT Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2024 to May 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2023 to May 2024